公开(公告)号：US12258382B2

公开(公告)日：2025-03-25

申请号：US17529322

申请日：2021-11-18

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Colette Song ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: C07K14/00 ,  A61K35/17 ,  A61K39/00 ,  C07K14/47 ,  C07K14/635 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C12N5/0783 ,  C12Q1/6886 ,  G01N33/574 ,  A61K38/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20250092104A1

公开(公告)日：2025-03-20

申请号：US18955513

申请日：2024-11-21

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Annika SONNTAG ,  Daniel Johannes KOWALEWSKI ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH ,  Colette SONG

IPC: C07K14/47 ,  A61K38/00 ,  A61K39/00 ,  C07K14/725 ,  C07K14/74 ,  C12N5/0783

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US12247057B2

公开(公告)日：2025-03-11

申请号：US17877515

申请日：2022-07-29

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette Song ,  Oliver Schoor ,  Jens Fritsche ,  Toni Weinschenk ,  Harpreet Singh

IPC: C07K14/47 ,  A61K38/00 ,  A61K39/00 ,  A61P35/00 ,  C07K7/06 ,  C07K14/54 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/10 ,  C12N15/115 ,  G01N33/574

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20250066422A1

公开(公告)日：2025-02-27

申请号：US18936387

申请日：2024-11-04

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Steffen WALTER ,  Jens FRITSCHE ,  Colette SONG ,  Harpreet SINGH

IPC: C07K7/08 ,  A61K35/17 ,  A61K38/17 ,  A61K39/00 ,  A61K45/06 ,  C07K7/06 ,  C07K14/725 ,  C12N5/0783 ,  C12N9/64

Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.

公开(公告)号：US12234298B2

公开(公告)日：2025-02-25

申请号：US17238787

申请日：2021-04-23

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni Weinschenk ,  Oliver Schoor ,  Claudia Trautwein ,  Norbert Hilf ,  Steffen Walter ,  Harpreet Singh

IPC: A61K38/00 ,  A61K35/17 ,  A61K39/00 ,  A61M5/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/74 ,  C12N5/0783 ,  C12N5/0784 ,  G01N33/574 ,  C07K7/00

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

公开(公告)号：US12234276B2

公开(公告)日：2025-02-25

申请号：US17345553

申请日：2021-06-11

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Colette Song ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K38/00 ,  A61K35/17 ,  A61K38/17 ,  A61K39/00 ,  C07K7/06 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6881 ,  G01N33/574 ,  A61K35/12 ,  C07K7/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US12186277B2

公开(公告)日：2025-01-07

申请号：US17743778

申请日：2022-05-13

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Colette Song ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K39/00 ,  A61K35/17 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/705 ,  C07K14/71 ,  C07K14/72 ,  C07K14/725 ,  C07K14/81 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K16/38 ,  C07K16/40 ,  C12N5/0783 ,  C12N9/02 ,  C12N9/12 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G16B25/00 ,  G16B25/10 ,  A61K38/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US12171819B2

公开(公告)日：2024-12-24

申请号：US17721573

申请日：2022-04-15

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Colette Song ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K38/00 ,  A61K39/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/705 ,  C07K14/71 ,  C07K14/72 ,  C07K14/725 ,  C07K14/81 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K16/38 ,  C07K16/40 ,  C12N5/0783 ,  C12N9/02 ,  C12N9/12 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G16B25/00 ,  G16B25/10 ,  A61K35/17

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20240358831A1

公开(公告)日：2024-10-31

申请号：US18685736

申请日：2022-08-24

Applicant: IMMATICS US, INC. ,  Immatics Biotechnologies GmbH

Inventor： Stefanie SPALT ,  Claudia WAGNER ,  Dominik MAURER ,  Heiko SCHUSTER ,  Steffen WALTER

IPC: A61K39/00 ,  C07K14/74 ,  C12N5/0783

CPC classification number: A61K39/4632 ,  A61K39/4611 ,  C07K14/70539 ,  C12N5/0636 ,  C12N2502/11

Abstract: The present invention relates to a method for selecting an immune cell expressing on its surface an antigen-binding protein specifically binding to a complex of a peptide A (PA) and a Major Histocompatibility Complex (MHC) molecule, comprising the steps of (i) providing a plurality of immune cells expressing different antigen-binding proteins; (ii) contacting the plurality of immune cells with a first composition comprising a complex 1A, comprising a MHC molecule 1 (M1) and a peptide A (PA), and a complex 1X, comprising M1 and a peptide B (PB); (iii) contacting the plurality of immune cells with a second composition comprising a complex 2A, comprising a MHC molecule 2 (M2) and PA, and a complex 2X, comprising M2 and a peptide C (PC); (iv) selecting from the plurality of immune cells a cell expressing an antigen binding protein that specifically binds to complex 1A, wherein complexes 1X and 2X, but not 1A and 2A, dissociate upon stimulation with a defined chemical or physical stimulus; and wherein the amino acid sequences of PB and PC differ in at least one amino acid. The invention further relates to an immune cell selected by the method according to the invention, a method of treatment using said immune cell, a kit for selecting a cell expressing on its surface an antigen-binding protein, and a peptide suitable for use in the method according to the invention.

公开(公告)号：US12121572B2

公开(公告)日：2024-10-22

申请号：US17502185

申请日：2021-10-15

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni Weinschenk ,  Andrea Mahr ,  Jens Fritsche ,  Phillip Mueller ,  Anita Wiebe ,  Sarah Kutscher

IPC: A61K39/00 ,  A61K35/17 ,  A61K38/04 ,  C07K7/00 ,  C07K7/06 ,  C07K14/435 ,  C07K14/725 ,  C07K14/74 ,  C07K16/18 ,  C12N5/0783 ,  C12N15/115 ,  A61K35/12 ,  A61K51/10 ,  C07K7/08 ,  G01N33/68

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/04 ,  C07K7/00 ,  C07K7/06 ,  C07K14/435 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/18 ,  C12N5/0636 ,  C12N15/115 ,  A61K2035/124 ,  A61K39/00111 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K51/1057 ,  C07K7/08 ,  C07K2317/70 ,  C07K2319/40 ,  C12N2310/16 ,  C12N2501/998 ,  G01N33/6803

Abstract: A peptide consists of the amino acid sequence GLIHLEGDTV (SEQ ID NO: 53) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8 T cells. A composition contains a peptide consisting of the amino acid sequence GLIHLEGDTV (SEQ ID NO: 53), an adjuvant, and a pharmaceutically acceptable carrier.